June 30th 2025
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
November 25th 2022“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.
Analysis shows promise of tivozanib in patients with nccRCC
November 22nd 2022“Due to the rarity and poor molecular characterization of nccRCC, there is an underrepresentation in clinical trials evaluating patients with this type of RCC; because of this, patients are often treated with non-tailored therapies,” the researchers wrote.
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
October 26th 2022Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
August 23rd 2022“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.
Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
April 22nd 2022Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Expert explains latest developments in surgical management of kidney cancer
March 18th 2022Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.